A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
The objective of this study was to assess the single dose bioequivalence of Roxane\'s Ropinirole tablets,0.25 mg, to ReQuip Tablets, 0.25 mg (GlaxoSmithKline) under fed conditions using a single dose, randomized, 2-treatment, 2-period, 2-sequence cross-over design.
Epistemonikos ID: 517c30d0f8c0055234153d6eb2346556175cf362
First added on: May 05, 2024